Edwards Lifesciences Corporation (NYSE:EW) VP Larry L. Wood sold 18,960 shares of the firm’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $108.54, for a total value of $2,057,918.40. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Larry L. Wood also recently made the following trade(s):
- On Friday, September 15th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $112.58, for a total value of $2,134,516.80.
- On Wednesday, August 30th, Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $111.81, for a total value of $2,119,917.60.
Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up 0.25% during trading on Monday, hitting $108.52. The stock had a trading volume of 790,162 shares. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.45. The company has a market cap of $22.91 billion, a P/E ratio of 32.91 and a beta of 0.62. The stock’s 50-day moving average price is $111.37 and its 200-day moving average price is $111.56.
Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842.00 million during the quarter, compared to analyst estimates of $839.16 million. During the same quarter last year, the firm earned $0.76 earnings per share. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts forecast that Edwards Lifesciences Corporation will post $3.78 EPS for the current fiscal year.
WARNING: This piece of content was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/16/edwards-lifesciences-corporation-ew-vp-larry-l-wood-sells-18960-shares-2.html.
Several hedge funds have recently bought and sold shares of EW. ETF Managers Group LLC acquired a new stake in shares of Edwards Lifesciences Corporation in the second quarter valued at about $112,000. Shine Investment Advisory Services Inc. acquired a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at approximately $126,000. Cornerstone Advisors Inc. grew its stake in Edwards Lifesciences Corporation by 25.1% during the 2nd quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after purchasing an additional 219 shares in the last quarter. Alexandria Capital LLC grew its stake in Edwards Lifesciences Corporation by 1.7% during the 2nd quarter. Alexandria Capital LLC now owns 1,146 shares of the medical research company’s stock valued at $136,000 after purchasing an additional 19 shares in the last quarter. Finally, MPS Loria Financial Planners LLC acquired a new stake in Edwards Lifesciences Corporation during the 2nd quarter valued at approximately $140,000. Institutional investors and hedge funds own 81.90% of the company’s stock.
A number of brokerages recently issued reports on EW. Bank of America Corp raised their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the stock a “buy” rating in a research report on Thursday, July 27th. BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. SunTrust Banks, Inc. raised their price objective on Edwards Lifesciences Corporation to $14.00 and gave the stock a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity reissued a “buy” rating and set a $155.00 price objective (up from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Finally, Royal Bank Of Canada reissued a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Friday, July 28th. Seven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $120.75.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.
Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.